• Potential new treatment option for multiple myeloma patients in Korea.
• Expanded patient access through competitive pricing.

SHANGHAI and NANJING, China and PLEASANTON, Calif., Oct. 29, 2025 /PRNewswire/ -- Nanjing IASO Biotechnology ("IASO Bio"), today announced that it has signed an agreement with Korea's GC Cell to introduce the CAR-T therapy...